Drug Profile
Research programme: stem cell-based therapeutics - Pluri
Alternative Names: Placenta expanded mesenchymal cells; Placental-derived mesenchymal stem cells; PLX-BMP; PLX-BMT; PLX-I; PLX-IBD; PLX-Immune; PLX-MS; PLX-ORTHO; PLX-PAH; PLX-STROKELatest Information Update: 13 Mar 2023
Price :
$50
*
At a glance
- Originator Pluristem Life Systems
- Developer Berlin-Brandenburg Center for Regenerative Therapies; Hebrew University of Jerusalem; New York University School of Medicine; Pluri; Texas A&M University; United Therapeutics Corporation
- Class Analgesics; Anti-inflammatories; Cardiovascular therapies; Neuroprotectants; Stem cell therapies
- Mechanism of Action Cell replacements; Dopaminergic cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Diabetic foot; Diastolic heart failure; Haematological malignancies; Inflammatory bowel diseases; Multiple sclerosis; Musculoskeletal disorders; Myocardial infarction; Neuropathic pain; Pain; Parkinson's disease; Preeclampsia; Pulmonary arterial hypertension; Pulmonary fibrosis; Stroke
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for preclinical development in Cancer in Israel (IM, Injection)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Multiple-sclerosis in Germany (IM)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Musculoskeletal-disorders in Israel (IM, Injection)